Soluble triggering receptor expressed on myeloid cell-1 reflects the cross-sectional activity of microscopic polyangiitis and granulomatosis with polyangiitis

[1]  P. R. Mertens,et al.  Monitoring disease activity in antineutrophil antibody‐associated vasculitis , 2023, Scandinavian journal of immunology.

[2]  Tian Liu,et al.  TREM-1 governs NLRP3 inflammasome activation of macrophages by firing up glycolysis in acute lung injury , 2023, International journal of biological sciences.

[3]  M. Brenner,et al.  TREM-1 Modulation Strategies for Sepsis , 2022, Frontiers in Immunology.

[4]  M. Brenner,et al.  A novel eCIRP/TREM-1 pathway inhibitor attenuates acute kidney injury. , 2022, Surgery.

[5]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis , 2022, Annals of the Rheumatic Diseases.

[6]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis , 2022, Annals of the Rheumatic Diseases.

[7]  A. Mebazaa,et al.  sTREM-1 is a specific biomarker of TREM-1 pathway activation , 2021, Cellular & Molecular Immunology.

[8]  E. Shin,et al.  Roles of Type I and III Interferons in COVID-19 , 2021, Yonsei medical journal.

[9]  Yong-Beom Park,et al.  Serological Biomarkers and Indices for the Current Activity and Prognosis of ANCA-Associated Vasculitis: Experience in a Single Centre in Korea , 2021, Yonsei medical journal.

[10]  Liling Tang,et al.  Function of TREM1 and TREM2 in Liver-Related Diseases , 2020, Cells.

[11]  F. Pinet,et al.  TREM-1 orchestrates Angiotensin II-induced monocyte trafficking and promotes experimental abdominal aortic aneurysm. , 2020, The Journal of clinical investigation.

[12]  P. Merkel,et al.  ANCA-associated vasculitis , 2020, Nature Reviews Disease Primers.

[13]  X. Solanich,et al.  Comparison of the Birmingham Vasculitis Activity Score and the Five‐Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry) , 2020, Arthritis care & research.

[14]  Ping Wang,et al.  Extracellular CIRP and TREM‐1 axis promotes ICAM‐1‐Rho‐mediated NETosis in sepsis , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  T. Mak,et al.  TREM-1-dependent M1 macrophage polarization restores intestinal epithelium damaged by DSS-induced colitis by activating IL-22-producing innate lymphoid cells , 2019, Journal of Biomedical Science.

[16]  S. Murthy,et al.  TREM‐1 regulates neutrophil chemotaxis by promoting NOX‐dependent superoxide production , 2019, Journal of leukocyte biology.

[17]  Mimi Zhang,et al.  Inhibition of TREM-1 attenuates early brain injury after subarachnoid hemorrhage via downregulation of p38MAPK/MMP-9 and preservation of ZO-1 , 2019, Neuroscience.

[18]  Yong-Beom Park,et al.  Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative Review , 2018, Yonsei medical journal.

[19]  S. Ajmani,et al.  Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCA-associated vasculitis , 2018, Clinical Rheumatology.

[20]  P. Messa,et al.  ANCA-associated vasculitis with renal involvement , 2018, Journal of Nephrology.

[21]  A. Heck,et al.  TREM-1 multimerization is essential for its activation on monocytes and neutrophils , 2018, Cellular & Molecular Immunology.

[22]  Lei Fu,et al.  Triggering Receptor Expressed on Myeloid Cells-1 Signaling: Protective and Pathogenic Roles on Streptococcal Toxic-Shock-Like Syndrome Caused by Streptococcus suis , 2018, Front. Immunol..

[23]  Hong Zhang,et al.  TREM-1 Contributes to Inflammation in IgA Nephropathy , 2018, Kidney Diseases.

[24]  M. Dessing,et al.  TREM‐1 and its potential ligands in non‐infectious diseases: from biology to clinical perspectives , 2017, Pharmacology & therapeutics.

[25]  T. Gheita,et al.  Clinical Association of a Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) in Patients with Systemic Lupus Erythematosus , 2017, Immunological investigations.

[26]  Tian Liu,et al.  Blocking triggering receptor expressed on myeloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation , 2016, Scientific Reports.

[27]  G. Xin,et al.  Reversal of TREM-1 ectodomain shedding and improved bacterial clearance by intranasal metalloproteinase inhibitors , 2016, Mucosal Immunology.

[28]  L. Davis,et al.  Blockade of CD354 (TREM-1) Ameliorates Anti-GBM-Induced Nephritis , 2016, Inflammation.

[29]  E. Essa,et al.  sTREM‐1 in patients with chronic kidney disease on hemodialysis , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[30]  D. Tarng,et al.  TREM-1 regulates macrophage polarization in ureteral obstruction. , 2014, Kidney international.

[31]  S. Gibot,et al.  Triggering receptor expressed on myeloid cells-1 (TREM-1): a new player in antiviral immunity? , 2014, Front. Microbiol..

[32]  R. Falk,et al.  Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease , 2014, Nature Reviews Rheumatology.

[33]  M. Colonna,et al.  Role of TREM1-DAP12 in Renal Inflammation during Obstructive Nephropathy , 2013, PloS one.

[34]  L. Joosten,et al.  TREM‐1: intracellular signaling pathways and interaction with pattern recognition receptors , 2013, Journal of leukocyte biology.

[35]  Y. Ha,et al.  Levels of Plasma-soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Are Correlated with Disease Activity in Rheumatoid Arthritis , 2012, The Journal of Rheumatology.

[36]  Y. Jung,et al.  Expression of a soluble triggering receptor expressed on myeloid cells‐1 (sTREM‐1) correlates with clinical disease activity in intestinal Behcet's disease , 2011, Inflammatory bowel diseases.

[37]  L. Mouthon,et al.  The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort , 2011, Medicine.

[38]  David Steven Scott,et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[39]  R. Luqmani,et al.  Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. , 2006, Clinical and experimental rheumatology.

[40]  D. Scott,et al.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.

[41]  T. Iwaya,et al.  Development of the Korean version of Short-Form 36-Item Health Survey: health related QOL of healthy elderly people and elderly patients in Korea. , 2004, The Tohoku journal of experimental medicine.

[42]  Sheng Gao,et al.  The characteristics and pivotal roles of triggering receptor expressed on myeloid cells-1 in autoimmune diseases. , 2019, Autoimmunity reviews.

[43]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.